| scholarly article | Q13442814 |
| P50 | author | Kimio Ushijima | Q90326451 |
| Toshiharu Kamura | Q114357818 | ||
| P2093 | author name string | Kyogo Itoh | |
| Shigeki Shichijo | |||
| Kouichiro Kawano | |||
| Satoko Matsueda | |||
| Takuto Yamashita | |||
| Tetsuro Sasada | |||
| Nobukazu Komatsu | |||
| Akimasa Fukui | |||
| Masato Yokomine | |||
| Kazuto Tasaki | |||
| Ken Matsukuma | |||
| P2860 | cites work | Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women | Q28251260 |
| Alphavirus Replicon Particles Expressing TRP-2 Provide Potent Therapeutic Effect on Melanoma through Activation of Humoral and Cellular Immunity | Q28749317 | ||
| Epidemiologic classification of human papillomavirus types associated with cervical cancer | Q29616213 | ||
| Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18 | Q33910699 | ||
| Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial | Q34415030 | ||
| Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases | Q34627305 | ||
| Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine | Q35757389 | ||
| Identification of B cell epitopes reactive to human papillomavirus type-16L1- derived peptides | Q36295220 | ||
| CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma | Q37260574 | ||
| A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. | Q37604389 | ||
| Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. | Q40572162 | ||
| Inclusion of a specific T cell epitope increases the protection conferred against foot-and-mouth disease virus in pigs by a linear peptide containing an immunodominant B cell site | Q42046690 | ||
| Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles | Q45406761 | ||
| Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial | Q45552005 | ||
| Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins | Q46650085 | ||
| Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication | Q47860026 | ||
| Long-term trends in cancer mortality in the United States, 1930-1998. | Q47863841 | ||
| HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. | Q51961251 | ||
| New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization | Q80569679 | ||
| Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up | Q83428460 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 1500-1505 | |
| P577 | publication date | 2017-02-21 | |
| P1433 | published in | Experimental and Therapeutic Medicine | Q23979083 |
| P1476 | title | Enhancement of humoral and cell mediated immune response to HPV16 L1-derived peptides subsequent to vaccination with prophylactic bivalent HPV L1 virus-like particle vaccine in healthy females | |
| P478 | volume | 13 |
| Q98163575 | Prevalence of antibodies against a cyclic peptide mimicking the FG loop of the human papillomavirus type 16 capsid among Tunisian women |
| Q55398396 | Proposal for cervical cancer screening in the era of HPV vaccination. |
| Q45324462 | The Rationale for a Preventative HCV Virus-Like Particle (VLP) Vaccine |
Search more.